Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lasofoxifene |
Synonyms | |
Therapy Description |
Lasofoxifene (CP 336156) is a selective estrogen response modulator (SERM) which binds to estrogen receptors and acts as an antagonist or agonist, and may decrease tumor growth (PMID: 11751385, PMID: 23604900). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lasofoxifene | CP 336156|CP-336,156|LAS|Oporia | Hormone - Anti-estrogens 29 | Lasofoxifene (CP 336156) is a selective estrogen response modulator (SERM) which binds to estrogen receptors and acts as an antagonist or agonist, and may decrease tumor growth (PMID: 11751385, PMID: 23604900). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03781063 | Phase II | Lasofoxifene Fulvestrant | Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Active, not recruiting | USA | ISR | CAN | 0 |